

N69 114947

Contents

1. Dedication	2
2. Abstract	7
3. Zusammenfassung	8
4. Introduction	10
4.1. Adipose tissue and sexual selection	10
4.2. Overweight, Obesity and T2DM	11
4.3. Energy Homeostasis and Obesity Development	12
4.4. Inflammation and development of T2DM	13
4.5. New hypothesis in fight against T2DM and Antioxidants	14
4.6. Central regulation of Obesity and T2DM	14
4.7. Treatment strategies against Obesity and T2DM	15
5. Aim of this work	16
6. FGF21, energy expenditure and weight loss - How much brown fat do you need?	17
6.1. Contributions	17
6.2. Abstract	17
6.3. Introduction	17
6.4. Identification of FGF21	19
6.5. Regulation of FGF21 expression	19
6.6. FGF21 signaling	20
6.7. FGF21 and brown fat uncoupling - new insights	20
6.8. Conclusions	22
7. An account of the adipose organ	23
7.1. Contributions	23
7.2. Abstract	23
7.3. Introduction	24
7.4. Materials and methods	25
7.4.1. Animals	25

7.4.2.	Quantification of CreERT2 recombination	26
7.4.3.	Histological analysis	26
7.4.4.	Statistical analysis	27
7.5.	Results	27
7.5.1.	Determination of adipocyte numbers with quantitative recombination assay	27
7.5.2.	Tamoxifen washout time assessment with Ucp1-tracer-deleter mouse model	29
7.5.3.	Cold-induced plasticity of iBAT and ingWAT	31
7.5.4.	Discussion	31
8.	Antioxidant cocktail prevents development of Diabetes caused by fat-specific insulin resistance	36
8.1.	Contributions	36
8.2.	Abstract	36
8.3.	Introduction	37
8.4.	Methods	38
8.4.1.	Animal work	38
8.4.2.	Indirect calorimetry	39
8.4.3.	Blood analysis	39
8.4.4.	Tissue triglyceride content	39
8.4.5.	Glucose Tolerance Test	40
8.4.6.	Insulin Tolerance Test	40
8.4.7.	Jugular Vein (JV) catheter	40
8.4.8.	Gavage of mice with jugular vein catheters	40
8.4.9.	Anaesthesia and analgesia	41
8.4.10.	Hyperinsulinemic euglycemic clamp	41
8.4.11.	Protein analysis	41
8.4.12.	RNA analysis	41
8.4.13.	Statistics	42
8.4.14.	ROS (H2O2) measurement	42
8.5.	Results	43
8.5.1.	Induction of adipocyte-specific knockout of IR receptor (iFIRKO) led to lipodystrophy	43
8.5.2.	iFIRKO changed metabolism and induced hyperglycemia, polydipsia and hyperphagia	43
8.5.3.	iFIRKO in high fat diet-induced obese mice repeatedly caused hyperglycemia	50
8.5.4.	iFIRKO in obese mice reduced RER and increased oxygen consumption	54
8.5.5.	iFIRKO before start of high fat diet feeding prevented the obesogenic effect of HFD feeding	56

8.5.6.	Antioxidant cocktail rescued hyperglycemia, hyperphagia and polydipsia in iFIRKO	57
8.5.7.	Antioxidant cocktail rescued hyperglycemia and hyperphagia in genetically obese mice (mouse model of Leptin mutation)	57
8.6.	Discussion	62

9.	Acknowledgement	66
A.	List of publications	69
	Bibliography	70
B.	Abbreviations	91
C.	Closing remarks	93